- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02898649
Safety and Efficacy of Irreversible Electroporation for Locally Advanced Pancreatic Cancer
Pancreatic cancer is 5th leading cause of cancer-related death in Korea. It has a dismal prognosis with very low 5-year survival rate, about 5%. Only 10% of pancreatic cancer patients is diagnosed in operable status. So, most of patients could not be treated with curative resection.
Locally advanced pancreatic cancer (LAPC) is defined by defined as surgically unresectable due to vascular encasement (e.g. celiac trunk or superior mesenteric artery) by tumor, but have no evidence of distant metastases. In LAPC patients, systemic chemotherapy with/without radiotherapy was used as a standard therapy, but therapeutic response was very poor. Only less than 30% of patients showed treatment response, and median survival of LAPC patient was only 9 months. Thus, more effective treatment modality is needed for LAPC patients.
Irreversible electroporation (IRE) is a soft tissue ablation technique using ultra short but strong electrical fields to create permanent and hence lethal nanopores in the cell membrane, to disrupt the cellular homeostasis. IRE does not cause thermally induced necrosis and has tissue selectivity, so adjacent tissue or vascular structures can be preserved.
Several clinical trials using IRE were performed to liver, kidney or lung cancer patients. We will operate IRE procedure to LAPC patients who were previously received standard therapy but showed no response, using NanoKnife IRE device. We will investigate treatment response and safety of IRE.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Seung Min Bang, MD
- Phone Number: +82 2 2228 1995
- Email: BANG7028@yuhs.ac
Study Locations
-
-
-
Seoul, Korea, Republic of, 03722
- Recruiting
- Yonsei university of medical center
-
Contact:
- Seung Min Bang, MD
- Phone Number: +82 2 2228 1995
- Email: BANG7028@yuhs.ac
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pathologically confirmed pancreatic cancer patients
- Locally advanced pancreatic cancer patients. Vascular encasement by tumor was noted in radiological evaluation (CT, MRI or PET-CT)
- Older than 19 years old and younger than 70 years old
- Previously treated with systemic chemotherapy or chemoradiotherapy due to locally advanced pancreatic cancer.
Exclusion Criteria:
- Patients with life-threatening systemic disease.
- Metastatic or borderline-resectable pancreatic cancer patients
- Patients with seizure history
- Patients with arrythmia or heart failure
- Recent history of myocardial infarction (within 1 year)
- Patients who have implantable electronic devices. (e.g. pacemaker, defibrillator)
- Patients who have metal devices (e.g. metal stent) around tumor.
- Coagulopathy patients.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IRE
The intervention group
|
IRE is operated to tumor under laparotomy or CT-guided percutaneous approach.
Unipolar (19G) or bipolar (16G) electrode probe is inserted to around tumor.
After insertion of probe, short duration (70-90㎲) of electric current (25~45A) is generated by IRE device (NanoKnife IRE device, AngioDynamics, Queens bury, New York).
It is possible to obtain a three-dimensional ablation zone using multiple electrode.
IRE can cause apoptosis of tumor cells, without adjacent tissue damage.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: from 1 month to 3 month
|
Overall survival is calculated from the date of informed consent acquisition until the date of death.
|
from 1 month to 3 month
|
Safety (frequency of procedure-related complication and death)
Time Frame: from 1 month to 3 month
|
Safety is evaluated by the frequency of procedure-related complication and death.
|
from 1 month to 3 month
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to progression
Time Frame: within 1 year
|
within 1 year
|
Tumor control
Time Frame: within 1 year
|
within 1 year
|
Pain control
Time Frame: within 1 year
|
within 1 year
|
Change in CA 19-9
Time Frame: within 1 year
|
within 1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 4-2015-0150
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Locally Advanced Pancreatic Cancer
-
Washington University School of MedicineNational Cancer Institute (NCI)RecruitingCervical Cancer | Pancreatic Cancer | Pancreas Cancer | Locally Advanced Cervical Carcinoma | Locally Advanced Cervical Cancer | Cancer of the Pancreas | Locally Advanced Pancreatic Carcinoma | Locally Advanced Pancreatic Cancer | Cancer of the Cervix | Locally Advanced Pancreas CancerUnited States
-
Michael ChuongNovoCure Ltd.RecruitingPancreas Cancer | Locally Advanced Pancreatic Adenocarcinoma | Locally AdvancedUnited States
-
UMC UtrechtRadboud University Medical Center; Catharina Ziekenhuis Eindhoven; Amsterdam... and other collaboratorsNot yet recruitingLocally Advanced Pancreatic Cancer After Systemic Therapy: Ablative MR-guided Radiotherapy (LAPSTAR)Locally Advanced Pancreatic AdenocarcinomaNetherlands
-
Institut du Cancer de Montpellier - Val d'AurelleRecruitingLocally Advanced Pancreatic AdenocarcinomaFrance
-
National Cancer Institute (NCI)SuspendedStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Locally Advanced Pancreatic Adenocarcinoma | Locally Advanced Unresectable Pancreatic Adenocarcinoma | Unresectable Pancreatic AdenocarcinomaUnited States
-
University of UtahNational Cancer Institute (NCI)Active, not recruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Borderline Resectable Pancreatic Adenocarcinoma | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Locally Advanced Unresectable Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Ductal...United States
-
Istituto Scientifico Romagnolo per lo Studio e...CompletedUnresectable Pancreatic Cancer | Locally Advanced Pancreatic Cancer | Nonmetastatic Pancreatic CancerItaly
-
Boryung Pharmaceutical Co., LtdRecruitingMetastatic Pancreatic Cancer | Locally Advanced Pancreatic CancerKorea, Republic of
-
AIO-Studien-gGmbHServier Deutschland GmbH; Crolll GmbhActive, not recruitingMetastatic Pancreatic Cancer | Locally Advanced Pancreatic CancerGermany
-
Yonsei UniversityActive, not recruitingMetastatic Pancreatic Cancer | Locally Advanced Pancreatic CancerKorea, Republic of
Clinical Trials on Irreversible electroporation
-
Fuda Cancer Hospital, GuangzhouCompleted
-
University Hospital Inselspital, BerneCantonal Hospital of St. Gallen; St. Claraspital AG; Cantonal Hospital of ZugTerminatedPancreatic CancerSwitzerland
-
University Hospital Inselspital, BerneTerminated
-
Assiut UniversityUnknown
-
University College London HospitalsUnknownProstate CancerUnited Kingdom
-
Jewish General HospitalNot yet recruiting
-
University Hospital Inselspital, BerneTerminated
-
Poitiers University HospitalSport & Collection 2019WithdrawnCholangiocarcinoma | Interventional Imaging
-
Memorial Sloan Kettering Cancer CenterCompletedColorectal Metastases to the LungUnited States
-
Clinical Research Office of the Endourological...Angiodynamics, Inc.CompletedProstate CancerNetherlands